| .png) | Product to Patient Partner with ICON to accelerate the development of your devices and diagnostics that save lives and improve quality of life. Learn More. |
Featured Story | By Ben Adams Though known more for its oncology and diabetes pipeline, AstraZeneca is now entering a new phase in obesity with a research pact penned with Regeneron. read more |
| |
|---|
|
Top Stories By Kyle LaHucik Biogen and partner Ionis Pharmaceuticals said their anti-tau antisense treatment candidate was safe and tolerable in a phase 1b study of patients with mild Alzheimer's disease. read more By Ben Adams Seven years ago, AbbVie penned an early-stage deal with Google/Alphabet’s life sciences division Calico: The pair have clearly enjoyed their time together, as they are penning a second extension for that collab. read more Sponsored By: Clever Leaves Medical cannabis from Colombia can change lives. read more By Nick Paul Taylor Organon has struck a deal to license the global rights to preterm labor prospect ebopiprant from ObsEva. The Merck spinout is set to pay $25 million upfront and commit to paying up to $475 million in milestones to take control of the prostaglandin F2α receptor antagonist. read more By Nick Paul Taylor Artios Pharma has raised $153 million to take its DNA damage response (DDR) pipeline deeper into the clinic. The series C positions Artios, which is run by some of the people behind pioneering DDR drug Lynparza, to test the effect of interfering with DNA double-strand break repair processes. read more By Amirah Al Idrus As SynOx Therapeutics gears up to test its anti-CSF1R antibody in registrational trials, the Dublin-based biotech is getting a pair of new leaders. Ray Barlow, formerly the chief business officer of Kiadis Pharma, signs on as CEO and Ton Logtenberg, Ph.D. becomes the company’s new non-executive chairman. read more By Amirah Al Idrus After 15 years of laying the groundwork, IMIDomics is coming out of the shadows with $16.5 million and a mission to bring precision medicine to inflammatory ailments such as Crohn’s disease, lupus and rheumatoid arthritis. read more By Kyle LaHucik Less than two months after Biogen received the FDA green light for its controversial Alzheimer's drug Aduhelm, competitor Prothena said preclinical studies of its own monoclonal antibody targeting amyloid-beta show that the drug binds to its target with about 11 times more strength than Biogen's does. read more By Andrea Park With five tuck-in acquisitions already under its belt for the year and no signs of slowing down, BD has made what may be its strongest buyout yet—literally. read more Resources Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Sponsored by: Evidera, a PDD business Learn about key post-marketing safety study solutions, including registries and REMS, and how they can most effectively help meet regulatory requirements and maximize patient access. Sponsored by: WCG Engage Independent Expert Endpoint Adjudication and Data Monitoring Committees in a strategic manner to identify methods for retrospective and prospective evaluations that may improve competitive advantage and bolster regulatory submissions. Sponsored by: Patheon by Thermo Fisher Scientific Take a closer look at your supply chain to ensure it delivers with speed, efficiency, and quality — all within budget. Sponsored by: Patheon by Thermo Fisher Scientific Choose the right AAV platform for your viral vector-based therapy Sponsored by: Blue Matter Consulting E-book to get newcomers “up to speed” quickly on digital health and digital therapeutics while also addressing key issues important to those already familiar with the topic. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process intesification Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. | 
